The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline

Amy M. West, Justin D. Anderson, Craig H. Meyer, Frederick H. Epstein, Hongkun Wang, Klaus D. Hagspiel, Stuart S. Berr, Nancy L. Harthun, Joseph M. DiMaria, Jennifer R. Hunter, John M. Christopher, Joshua D. Chew, Gabriel B. Winberry, Christopher M. Kramer

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: Both statins and ezetimibe lower LDL-C, but ezetimibe's effect on atherosclerosis is controversial. We hypothesized that lowering LDL-C cholesterol by adding ezetimibe to statin therapy would regress atherosclerosis measured by magnetic resonance imaging (MRI) in the superficial femoral artery (SFA) in peripheral arterial disease (PAD). Methods: Atherosclerotic plaque volume was measured in the proximal 15-20. cm of the SFA in 67 PAD patients (age 63 ± 10, ABI 0.69 ± 0.14) at baseline and annually × 2. Statin-naïve patients (n=34) were randomized to simvastatin 40. mg (S, n=16) or simvastatin 40 mg + ezetimibe 10 mg (S + E, n=18). Patients already on statins but with LDL-C >80. mg/dl had open-label ezetimibe 10. mg added (E, n=33). Repeated measures models estimated changes in plaque parameters over time and between-group differences. Results: LDL-C was lower at year 1 in S+E (67±7mg/dl) than S (91±8mg/dl, p<0.05), but similar at year 2 (68±10mg/dl vs. 83±11mg/dl, respectively). Plaque volume did not change from baseline to year 2 in either S+E (11.5±1.4-10.5±1.3cm 3, p=NS) or S (11.0±1.5-10.5±1.4cm 3, p=NS). In E, plaque progressed from baseline to year 2 (10.0±0.8-10.8±0.9, p<0.01) despite a 22% decrease in LDL-C. Conclusions: Statin initiation with or without ezetimibe in statin-naïve patients halts progression of peripheral atherosclerosis. When ezetimibe is added to patients previously on statins, peripheral atherosclerosis progressed. Thus, ezetimibe's effect on peripheral atherosclerosis may depend upon relative timing of statin therapy. Clinical Trial Registration Information - NCT00587678 http://clinicaltrials.gov/ct2/show/NCT00587678.

Original languageEnglish (US)
Pages (from-to)156-162
Number of pages7
JournalAtherosclerosis
Volume218
Issue number1
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Atherosclerosis
montirelin
Simvastatin
Peripheral Arterial Disease
Femoral Artery
Ezetimibe
Atherosclerotic Plaques
LDL Cholesterol
Magnetic Resonance Imaging
Clinical Trials
Therapeutics

Keywords

  • Atherosclerosis
  • Lipids
  • Magnetic resonance imaging
  • Peripheral vascular disease
  • Plaque

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

West, A. M., Anderson, J. D., Meyer, C. H., Epstein, F. H., Wang, H., Hagspiel, K. D., ... Kramer, C. M. (2011). The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis, 218(1), 156-162. https://doi.org/10.1016/j.atherosclerosis.2011.04.005

The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. / West, Amy M.; Anderson, Justin D.; Meyer, Craig H.; Epstein, Frederick H.; Wang, Hongkun; Hagspiel, Klaus D.; Berr, Stuart S.; Harthun, Nancy L.; DiMaria, Joseph M.; Hunter, Jennifer R.; Christopher, John M.; Chew, Joshua D.; Winberry, Gabriel B.; Kramer, Christopher M.

In: Atherosclerosis, Vol. 218, No. 1, 09.2011, p. 156-162.

Research output: Contribution to journalArticle

West, AM, Anderson, JD, Meyer, CH, Epstein, FH, Wang, H, Hagspiel, KD, Berr, SS, Harthun, NL, DiMaria, JM, Hunter, JR, Christopher, JM, Chew, JD, Winberry, GB & Kramer, CM 2011, 'The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline', Atherosclerosis, vol. 218, no. 1, pp. 156-162. https://doi.org/10.1016/j.atherosclerosis.2011.04.005
West, Amy M. ; Anderson, Justin D. ; Meyer, Craig H. ; Epstein, Frederick H. ; Wang, Hongkun ; Hagspiel, Klaus D. ; Berr, Stuart S. ; Harthun, Nancy L. ; DiMaria, Joseph M. ; Hunter, Jennifer R. ; Christopher, John M. ; Chew, Joshua D. ; Winberry, Gabriel B. ; Kramer, Christopher M. / The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. In: Atherosclerosis. 2011 ; Vol. 218, No. 1. pp. 156-162.
@article{317e195cd88646a480f72415419cd924,
title = "The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline",
abstract = "Background: Both statins and ezetimibe lower LDL-C, but ezetimibe's effect on atherosclerosis is controversial. We hypothesized that lowering LDL-C cholesterol by adding ezetimibe to statin therapy would regress atherosclerosis measured by magnetic resonance imaging (MRI) in the superficial femoral artery (SFA) in peripheral arterial disease (PAD). Methods: Atherosclerotic plaque volume was measured in the proximal 15-20. cm of the SFA in 67 PAD patients (age 63 ± 10, ABI 0.69 ± 0.14) at baseline and annually × 2. Statin-na{\"i}ve patients (n=34) were randomized to simvastatin 40. mg (S, n=16) or simvastatin 40 mg + ezetimibe 10 mg (S + E, n=18). Patients already on statins but with LDL-C >80. mg/dl had open-label ezetimibe 10. mg added (E, n=33). Repeated measures models estimated changes in plaque parameters over time and between-group differences. Results: LDL-C was lower at year 1 in S+E (67±7mg/dl) than S (91±8mg/dl, p<0.05), but similar at year 2 (68±10mg/dl vs. 83±11mg/dl, respectively). Plaque volume did not change from baseline to year 2 in either S+E (11.5±1.4-10.5±1.3cm 3, p=NS) or S (11.0±1.5-10.5±1.4cm 3, p=NS). In E, plaque progressed from baseline to year 2 (10.0±0.8-10.8±0.9, p<0.01) despite a 22{\%} decrease in LDL-C. Conclusions: Statin initiation with or without ezetimibe in statin-na{\"i}ve patients halts progression of peripheral atherosclerosis. When ezetimibe is added to patients previously on statins, peripheral atherosclerosis progressed. Thus, ezetimibe's effect on peripheral atherosclerosis may depend upon relative timing of statin therapy. Clinical Trial Registration Information - NCT00587678 http://clinicaltrials.gov/ct2/show/NCT00587678.",
keywords = "Atherosclerosis, Lipids, Magnetic resonance imaging, Peripheral vascular disease, Plaque",
author = "West, {Amy M.} and Anderson, {Justin D.} and Meyer, {Craig H.} and Epstein, {Frederick H.} and Hongkun Wang and Hagspiel, {Klaus D.} and Berr, {Stuart S.} and Harthun, {Nancy L.} and DiMaria, {Joseph M.} and Hunter, {Jennifer R.} and Christopher, {John M.} and Chew, {Joshua D.} and Winberry, {Gabriel B.} and Kramer, {Christopher M.}",
year = "2011",
month = "9",
doi = "10.1016/j.atherosclerosis.2011.04.005",
language = "English (US)",
volume = "218",
pages = "156--162",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline

AU - West, Amy M.

AU - Anderson, Justin D.

AU - Meyer, Craig H.

AU - Epstein, Frederick H.

AU - Wang, Hongkun

AU - Hagspiel, Klaus D.

AU - Berr, Stuart S.

AU - Harthun, Nancy L.

AU - DiMaria, Joseph M.

AU - Hunter, Jennifer R.

AU - Christopher, John M.

AU - Chew, Joshua D.

AU - Winberry, Gabriel B.

AU - Kramer, Christopher M.

PY - 2011/9

Y1 - 2011/9

N2 - Background: Both statins and ezetimibe lower LDL-C, but ezetimibe's effect on atherosclerosis is controversial. We hypothesized that lowering LDL-C cholesterol by adding ezetimibe to statin therapy would regress atherosclerosis measured by magnetic resonance imaging (MRI) in the superficial femoral artery (SFA) in peripheral arterial disease (PAD). Methods: Atherosclerotic plaque volume was measured in the proximal 15-20. cm of the SFA in 67 PAD patients (age 63 ± 10, ABI 0.69 ± 0.14) at baseline and annually × 2. Statin-naïve patients (n=34) were randomized to simvastatin 40. mg (S, n=16) or simvastatin 40 mg + ezetimibe 10 mg (S + E, n=18). Patients already on statins but with LDL-C >80. mg/dl had open-label ezetimibe 10. mg added (E, n=33). Repeated measures models estimated changes in plaque parameters over time and between-group differences. Results: LDL-C was lower at year 1 in S+E (67±7mg/dl) than S (91±8mg/dl, p<0.05), but similar at year 2 (68±10mg/dl vs. 83±11mg/dl, respectively). Plaque volume did not change from baseline to year 2 in either S+E (11.5±1.4-10.5±1.3cm 3, p=NS) or S (11.0±1.5-10.5±1.4cm 3, p=NS). In E, plaque progressed from baseline to year 2 (10.0±0.8-10.8±0.9, p<0.01) despite a 22% decrease in LDL-C. Conclusions: Statin initiation with or without ezetimibe in statin-naïve patients halts progression of peripheral atherosclerosis. When ezetimibe is added to patients previously on statins, peripheral atherosclerosis progressed. Thus, ezetimibe's effect on peripheral atherosclerosis may depend upon relative timing of statin therapy. Clinical Trial Registration Information - NCT00587678 http://clinicaltrials.gov/ct2/show/NCT00587678.

AB - Background: Both statins and ezetimibe lower LDL-C, but ezetimibe's effect on atherosclerosis is controversial. We hypothesized that lowering LDL-C cholesterol by adding ezetimibe to statin therapy would regress atherosclerosis measured by magnetic resonance imaging (MRI) in the superficial femoral artery (SFA) in peripheral arterial disease (PAD). Methods: Atherosclerotic plaque volume was measured in the proximal 15-20. cm of the SFA in 67 PAD patients (age 63 ± 10, ABI 0.69 ± 0.14) at baseline and annually × 2. Statin-naïve patients (n=34) were randomized to simvastatin 40. mg (S, n=16) or simvastatin 40 mg + ezetimibe 10 mg (S + E, n=18). Patients already on statins but with LDL-C >80. mg/dl had open-label ezetimibe 10. mg added (E, n=33). Repeated measures models estimated changes in plaque parameters over time and between-group differences. Results: LDL-C was lower at year 1 in S+E (67±7mg/dl) than S (91±8mg/dl, p<0.05), but similar at year 2 (68±10mg/dl vs. 83±11mg/dl, respectively). Plaque volume did not change from baseline to year 2 in either S+E (11.5±1.4-10.5±1.3cm 3, p=NS) or S (11.0±1.5-10.5±1.4cm 3, p=NS). In E, plaque progressed from baseline to year 2 (10.0±0.8-10.8±0.9, p<0.01) despite a 22% decrease in LDL-C. Conclusions: Statin initiation with or without ezetimibe in statin-naïve patients halts progression of peripheral atherosclerosis. When ezetimibe is added to patients previously on statins, peripheral atherosclerosis progressed. Thus, ezetimibe's effect on peripheral atherosclerosis may depend upon relative timing of statin therapy. Clinical Trial Registration Information - NCT00587678 http://clinicaltrials.gov/ct2/show/NCT00587678.

KW - Atherosclerosis

KW - Lipids

KW - Magnetic resonance imaging

KW - Peripheral vascular disease

KW - Plaque

UR - http://www.scopus.com/inward/record.url?scp=80052094401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052094401&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2011.04.005

DO - 10.1016/j.atherosclerosis.2011.04.005

M3 - Article

C2 - 21570685

AN - SCOPUS:80052094401

VL - 218

SP - 156

EP - 162

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -